R&D channel feed

Fi­bro­Gen eyes re­bound path with Ph1 ADC da­ta for prostate can­cer drug

Last year

Al­terome rais­es $132M to take next-gen can­cer drugs aimed at the 'un­drug­gable' in­to clin­ic

Last year
Financing

Ad­di­tion­al drug­mak­ers flag risks of work­ing with WuXi amid height­ened US scruti­ny

Last year
Pharma
Manufacturing

Grit­stone's Phase 2 can­cer vac­cine tri­al miss­es the mark, stock spi­rals down

Last year

Verve paus­es lead base edit­ing pro­gram af­ter safe­ty event, switch­es fo­cus to fol­low-up can­di­date near clin­ic

Last year
Cell/Gene Tx

Roivant an­nounces study win in eye dis­ease for Pfiz­er as­set, plans $1.5B share buy­back

Last year
Deals

Caris­ma to lay off staff, drop clin­i­cal CAR-M pro­gram in fa­vor of sec­ond can­di­date

Last year
People
Cell/Gene Tx

Disc Med­i­cine blames 'out­sized' place­bo re­sponse on mixed Phase 2 da­ta in rare blood dis­or­der

Last year

Q&A: In­sitro CEO Daphne Koller on ‘po­ten­tial­ly de­struc­tive’ AI hype, Nvidi­a's chips, and biotech's da­ta prob­lem

Last year
People

Car­lyle’s Abing­worth will help fund Te­va’s Phase 3 asth­ma res­cue in­haler

Last year
Deals
Pharma

Bris­tol My­er­s' Zeposia ex­pan­sion plans hit by Phase 3 set­back in Crohn's dis­ease

Last year
Pharma

Aldeyra to run an­oth­er tri­al for its dry eye dis­ease drug as part of re­sub­mis­sion plans

Last year

Here's how Mod­er­na is think­ing about the fu­ture of its vac­cines

Last year

With GIP, obe­si­ty re­search is at odds

Last year
In Focus

Up­dat­ed: Mod­er­na part­ners with Black­stone on flu shots, nab­bing up to $750M in R&D fund­ing

Last year
Financing
Deals

Atai Life Sci­ences spot­lights ear­ly de­pres­sion da­ta for psy­che­del­ic ahead of big read­out

Last year

Al­tim­mune cuts he­pati­tis B pro­gram, high­lights mus­cle preser­va­tion on obe­si­ty drug in da­ta up­date

Last year

Pfiz­er stops one of two Phase 3 tri­als for sick­le cell drug, still plans to seek ap­proval in 2026

Last year
Pharma

Viking Ther­a­peu­tics plans Ph2 tri­al for oral obe­si­ty drug af­ter pos­i­tive ear­ly-stage da­ta

Last year

Prax­is touts topline da­ta for epilep­sy drug in first of four read­outs

Last year

Stoke un­veils new da­ta on ge­net­ic epilep­sy drug — and in­vestors are stoked

Last year

Alex­ion adds fourth in­di­ca­tion for C5 in­hibitor Ul­tomiris in rare au­toim­mune dis­or­der

Last year
Pharma

In­vivyd scores EUA for Covid-19 pre­ven­tion drug Pem­gar­da

Last year

In small ac­qui­si­tion, Ab­b­Vie adds Lan­dos and its IBD drug to post-Hu­mi­ra plans

Last year
Deals
First page Previous page 47484950515253 Next page Last page
A service from the Financial Times